Fa'ata'ita'iga Falema'i Fa'ataunu'uina Numera Fa'atatau o Ma'i mo Su'esu'ega ile Fa'ama'i ole Alzheimer

Synaptogenix, Inc. i aso nei ua faʻailoa mai ua maeʻa ona lesitalaina lana faʻamoemoe o le 100 tagata maʻi mo ana National Institutes of Health (“NIH”) lagolagoina le Vaega 2b faʻataʻitaʻiga falemaʻi o Bryostatin-1 mo tagata mamaʻi o loʻo mafatia i faʻamaʻi faʻamaʻi faʻamaʻi ma feololo (AD). ”). O loʻo faʻamoemoe le Kamupani e faʻasalalau faʻamaumauga pito i luga mai le suʻesuʻega i le kuata lona fa o le 2022.

Ua lipotia mai foi e Synaptogenix e faapea o le Komiti Tutoatasi o le Mataituina o le Saogalemu o Faamatalaga (“DSMB”) o loo vaavaaia le faamasinoga ua faamaonia ai le leai o ni faafitauli tau le saogalemu o fualaau faasaina.

O le Bryostatin-1 na mafua ai le faʻaleleia atili o le mafaufau (4.0 SIB psychometric score i luga aʻe o le laina faʻavae) mo tagata mamaʻi na faʻamaonia muamua na mauaina le Bryostatin-1 i le toesea o Namenda i a matou faʻataʻitaʻiga pailate 3-masina muamua, faʻasalalau talu ai nei i se tupulaga- toe iloilo tala (JAD, 2022) - aʻo faʻataʻitaʻiina e le Placebo maʻi e leai se aoga taua. O le togafitiga Bryostatin-1 ua faʻalauteleina nei e aofia ai le faaluaina o numera o doses (N = 14) i le 6-masina o loʻo iai nei, faʻataʻitaʻiga placebo, lea na faʻatonutonuina ma le faʻaeteete le lesitalaina faʻapitoa mo laina paleni paleni i togafitiga ma placebo cohorts. O ma'i o le a mata'ituina mo le umi e tolu masina talu ona fa'agata uma tui, ona o le fa'aauau pea o le manuia mo le itiiti ifo i le 30 aso talu ona tu'uina atu lea sa matauina muamua.

"Ua faʻamalosia i matou o faʻamaumauga pito i luga e tatau ona totogi i le kuata lona 4, 2022, o le a atagia mai ai le tutusa pe sili atu faʻamanuiaga ua uma ona matauina mo tagata mamaʻi i faʻataʻitaʻiga tutusa, na togafitia muamua i a matou faʻataʻitaʻiga pailate Phase 2a muamua. O le leai o so'o se fa'alavelave fa'aleagaina e fa'atatau i vaila'au, e pei ona matauina i nai isi togafiti fa'ata'ita'iga e o'o atu i le fa'atapula'aina o le Food and Drug Administration ("FDA") fa'atagaina mo AD, e tatau ona fa'afaigofie a tatou la'asaga mulimuli ane i le fa'aogaina o falema'i. O faʻamanuiaga a itiiti ifo i le 4.0 SIB togi, i luga aʻe o le laina faʻavae, e foliga mai e aoga tele, ma o le mea lea e mafai ai ona togafitia le faʻamaʻi o loʻo aʻafia ai faʻapea foʻi ma le tuʻuina atu o se mapusaga faʻapitoa, "o le tala lea a Daniel Alkon, MD, le Peresetene o le Kamupani ma le Ofisa Sili Scientific Officer. .

Alan Tuchman MD, le Ofisa Sili o Pulega a le Kamupani, na taʻua, "O faʻamaoniga o loʻo faʻatupulaia ma faʻaauau pea ona lagolagoina le Bryostatin-1 e avea o se togafitiga talafeagai mo le faʻamaʻi o le Alzheimer. Matou te fiafia i aso nei e faʻasalalau le maeʻa o la matou Vaega 2b lesitala ma o loʻo matou faʻatali ma le naunautai i le faitau mai o matou laina pito i luga faʻamaumauga mulimuli ane i lenei tausaga.